Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia research"
DOI: 10.1016/j.leukres.2018.07.005
Abstract: The combination of 5-azacytidine (AZA) with donor lymphocyte infusions (DLIs) can induce remissions in patients with relapsed myeloid malignancies after allo-HCT. As decitabine (DAC) is known to be effective also in AML/MDS with leukocytosis, we… read more here.
Keywords: combination; allo hct; lymphocyte infusions; donor lymphocyte ... See more keywords
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021010867
Abstract: Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune checkpoint blockade (ICB) in this clinical setting with ipilimumab or nivolumab. To define the molecular… read more here.
Keywords: molecular cellular; blockade; cellular features; cell ... See more keywords